ERBB2 and neoplasm: By utilizing the tyrosine kinase inhibitors (e.g., gefitinib and erlotinib) or monoclonal antibodies (e.g., cetuximab and trastuzumab), they can inhibit the activities of EGFR/ERBB2 to effectively suppress the tumor cell growth [48, 49].